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Abstract
Background: Mental and neurological (MN) health care has long been neglected in low-income set-
tings. This paper estimates health and non-health impacts of fully publicly financed care for
selected key interventions in the National Mental Health Strategy in Ethiopia for depression, bipolar
disorder, schizophrenia and epilepsy.
Methods: A methodology of extended cost-effectiveness analysis (ECEA) is applied to MN health
care in Ethiopia. The impact of providing a package of selected MN interventions free of charge in
Ethiopia is estimated for: epilepsy (75% coverage, phenobarbital), depression (30% coverage, flu-
oxetine, cognitive therapy and proactive case management), bipolar affective disorder (50% cover-
age, valproate and psychosocial therapy) and schizophrenia (75% coverage, haloperidol plus psy-
chosocial treatment). Multiple outcomes are estimated and disaggregated across wealth quintiles:
(1) healthy-life-years (HALYs) gained; (2) household out-of-pocket (OOP) expenditures averted; (3)
expected financial risk protection (FRP); and (4) productivity impact.
Results: The MN package is expected to cost US$177 million and gain 155,000 HALYs (epilepsy
US$37m and 64,500 HALYs; depression US$65m and 61,300 HALYs; bipolar disorder US$44m and
20,300 HALYs; and schizophrenia US$31m and 8,900 HALYs) annually. The health benefits would
be concentrated among the poorest groups for all interventions. Universal public finance averts lit-
tle household OOP expenditures and provides minimal FRP because of the low current utilization
of these MN services in Ethiopia. In addition, economic benefits of US$ 51 million annually are
expected from depression treatment in Ethiopia as a result of productivity gains, equivalent to 78%
of the investment cost.
Conclusions: The total MN package in Ethiopia is estimated to cost equivalent to US$1.8 per capita
and yields large progressive health benefits. The expected productivity gain is substantially higher
than the expected FRP. The ECEA approach seems to fit well with the current policy challenges and
captures important equity concerns of scaling up MN programmes.
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Introduction
High quality health service delivery for mental and neurological
(MN) disorders in low-income settings is likely to bring large health
and non-health outcomes. Treatment demand is high and current
coverage is low. Depression, schizophrenia, bipolar disorders and
epilepsy cause around 13% of all Years of Life Lost due to
Disability (YLD) in Sub-Saharan Africa (SSA) according to 2013 es-
timates (Global Burden of Disease Study, 2015). Little is known
about the return on investing in MN programmes in low-income
countries. Such information is needed for making evidence based in-
vestments in MN health care. We aim to explore a novel approach
for measuring equity relevant policy impacts of scaling up MN ser-
vices in one particular low-income country.
Ethiopia is used as a case for testing how health and non-health
outcomes could be measured. There are only 0.4 specialists in
psychiatry per one million population in Ethiopia (Strand et al.
2015). The annual total health budget in Ethiopia is low (US$25
per capita) (World Bank and World Development Indicators). The
National Mental Health Strategy in Ethiopia specifies a massive
scale-up of psychiatric and psychological care during the next dec-
ade (Saxena et al. 2007; mhGAP-Ethiopia Working Group, 2010;
Bruckner et al. 2011; Federal Democratic Republic of Ethiopia
Ministry of Health, 2012). Shortage of human resources, low
health budgets and ambitious policy goals stresses the need for evi-
dence on the opportunity cost of MN interventions in Ethiopia, as
well as other low-income settings (Jamison et al. 2013). The im-
portance of both efficient and equitable scale-up of mental health
care is explicitly recognized in the suggested scale-up of services
for MN disorders.
Standard cost-effectiveness analyses (CEAs) are relevant for mak-
ing rank orders on which interventions that maximizes health out-
comes the most (Drummond et al. 2005). However, equity concerns
are not explicitly addressed in CEAs (Norheim et al. 2014; Brock and
Wikler, 2006; Jamison et al. 2013). Information on health inequality
among income groups and medical impoverishment are important in
addition to cost-effectiveness (Brock 2003; Daniels 2008). Direct out-
of-pocket (OOP) payments affect those least able to afford care and
are an important risk factor for health-care-induced impoverishment.
The reduction or elimination of private OOP expenditures to health
care can represent major financial savings for affected households.
Public financing of health service costs can also increase the use of ser-
vices, especially for those whose incomes are so low that they do not
access services in the first place. Prepayment mechanisms, such as na-
tional or social insurance, create safety nets for at-risk populations
from the adverse financial consequences of mental disorders.
Information on efficient purchase of equity concerns like financial
risk protection (FRP) and distribution of benefits across income
groups is needed in evidence-based policy decision making (World
Health Organisation, 2014).
Our application of extended cost-effectiveness analysis (ECEA)
to MN disorders focuses on universal public financing as an instru-
ment for FRP (Verguet et al. 2015a, b). Public financing provides
FRP benefits to households by reducing the financial burden due to
disease and the impoverishment-related consequences of the covered
health care service. A large proportion of total health spending in
Ethiopia is currently from OOP expenditures, the estimates vary be-
tween 30-40% over the last ten years (World Bank and World
Development Indicators, Federal Democratic Republic of Ethiopia
Ministry of Health, 2014). ECEA take the distribution of household
costs and health outcomes across different socioeconomic groups in
the population into account, but also explicitly examines the extent
to which interventions or policies protect households against the fi-
nancial risk of medical impoverishment (Verguet et al. 2015a,b).
Important equity concerns can be integrated into policy decision-
making quantitatively by ECEA methods. Few ECEAs are available
for mental health care.
The basic scale-up scenario in the National Mental Health
Strategy in Ethiopia targets treatment for depression, psychosis, bi-
polar disorder and epilepsy; key interventions in the World Health
Organization (WHO) mental health Gap Action Programme
(mh-GAP) (mhGAP-Ethiopia Working Group, 2010). Recent evi-
dence on cost-effectiveness of the basic scale-up scenario indicates
that treatment of depression, bipolar disorder, epilepsy and schizo-
phrenia cost between US$300 and US$2000 per Disability Adjusted
Life Year (DALY) averted (Reinap et al. 2005; World Health
Organization, 2006; Gureje et al. 2007; Ayuso-Mateos et al. 2008;
Chisholm et al. 2008; Salomon et al. 2012; Chisholm and Saxena
2012; Strand et al. 2015). Antipsychotics for schizophrenia are in
the upper cost-effectiveness range and phenobarbital for epilepsy is
in the lower cost-effectiveness range.
The objective of this paper is to apply ECEA methods to evaluate
scale-up and universal public finance – government financing of all
intervention costs irrespective of who is receiving care – of an MN
package of interventions that are specified as a key in the National
Mental Health Strategy in Ethiopia. With universal public finance,
households would receive treatment of epilepsy, depression, schizo-
phrenia and bipolar disorders free of charge at the point of care.
Since this approach of extending results from an existing CEA is
new and there are a few applications to MN disorders, we intended
to test the applicability of this method.
Methods
We use ECEA methods (Verguet et al. 2013, 2015a,b) to evaluate
the health and non-health impacts of increased coverage of the
MN treatment package: phenobarbital for epilepsy, fluoxetine com-
bined with cognitive therapy and proactive case management for de-
pression, valproate combined with psychosocial therapy for bipolar
Key Messages
• The National Mental Health Strategy in Ethiopia for depression, bipolar disorder, schizophrenia and epilepsy is esti-
mated to cost equivalent to US$1.8 per capita and to yield large progressive health benefits.
• A 78% overall rate of return (US$50M annually) to investment is expected from depression treatment in Ethiopia due to
productivity gains.
• Universal public finance provides minimal financial risk protection because of the low current utilization of mental and
neurological services in Ethiopia.
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affective disorder, and first-line antipsychotic medication (haloperi-
dol or chlorpromazine) plus psychosocial treatment for schizophre-
nia. Interventions in the analysed packages were selected in
accordance with recommendations in the National Mental Health
strategy in Ethiopia (Federal Democratic Republic of Ethiopia
Ministry of Health, 2012). All selected interventions have been
analysed in an existing standard CEA contextualized for an
Ethiopian setting, and in this ECEA we analyse the interventions
that were found to be most cost-effective for each condition (Strand
et al. 2015). The disease-specific incremental cost-effectiveness ratio
(ICER) for each of the selected interventions is estimated by (Strand
et al. 2015) to be: US$321 (phenobarbital for epilepsy); US$1026
(fluoxetine combined with cognitive therapy and proactive case
management for depression); US$2023 (valproate combined with
psychosocial therapy for bipolar affective disorder); and US$2001
(first-line antipsychotic medication plus psychosocial treatment for
schizophrenia).
The ECEA builds on the parent CEA of MN health care in
Ethiopia (Strand et al. 2015). The existing model is a generalized
WHO-CHOICE CEA (World Health Organisation and WHO-
CHOICE, 2016) that is contextualized to an Ethiopian setting. A mix
of primary cost data and secondary data sources were used in the ori-
ginal CEA (regional WHO-CHOICE dataset and empirical literature).
More details on this population-based multi-state analytical health
economic model can be found in the CEA study (Strand et al. 2015).
Healthy life years across income groups
In this ECEA, health benefits are measured in healthy life years
gained from interventions as compared to a null scenario if no
interventions are scaled-up. Treatment effects are incremental
reductions in case fatality, prevalence or disability weight, or
increased remission rates, by the respective MN interventions. We
split the Ethiopian population into five income quintiles and run
the existing analytical model (Strand et al. 2015) for each income
group with quintile-specific prevalence rates. Table 1 shows details
on parameter assumptions. The model has a life table structure
that includes disability weights to estimate healthy life years
(World Health Organisation and Department of Health Statistics
and Information Systems, 2014). The interventions are imple-
mented over a 10-year period, but health benefits are counted over
a lifetime. Healthy life years are discounted at 3% and no age-
weights are used.
There is one model for depression, one for bipolar disorder, one
for schizophrenia and one for epilepsy. The population in each of
these models is divided into three health states (disease X, suscep-
tible without disease X and dead). Transitions between health states
occur annually and are determined by the disease-specific preva-
lence, remission rates, case fatality rates and age-specific mortality
rates. The average age-specific disease prevalence used in the stand-
ard CEA (Strand et al. 2015) is adjusted to income-quintile-specific
prevalence rates, using a population-based prevalence study con-
ducted in Ethiopia (n¼1,497) (Fekadu et al. 2014). For each dis-
order, based on data extracted from (Fekadu et al. 2014), we obtain
a prevalence ratio by income quintile (poorest-quintile, 1.4; second-
poorest, 1.2; middle-quintile, 1; second-richest quintile, 0.8; and
richest-quintile, 0.6) and apply this to the mean age-specific preva-
lence of each disorder. Disease-specific mortality, disability weights,
intervention coverage and intervention effectiveness are held con-
stant in each income group.
Current treatment coverage for all disorders is<5% (Strand et
al. 2015). Following the introduction of universal public finance,
and in line with the National Mental Health Strategy, coverage for
all income groups is modelled to reach 75% for treatment of
schizophrenia and epilepsy, 50% for treatment of bipolar disorder
and 30% for treatment of depression (Federal Democratic
Republic of Ethiopia Ministry of Health 2012). Target coverage
for depression is lower than the target coverage for the other
interventions because the relatively high prevalence and low
detectability of depression. Estimates of the efficacy of interven-
tions were drawn from systematic reviews, meta-analyses and
randomized controlled (see Table 1) trials (full details can be found
in (Strand et al. 2015)).
Health provider costs
Unit costs (US$2010) from the original CEA are used (see Table 1)
and converted to US$2014 by a consumer price index GDP defla-
tor (World Bank and World Development Indicators 2015). The
original CEA has a health provider perspective on costs. By large,
unit prices (e.g. lab costs, pharmaceuticals, salaries) and quantities
needed at the various delivery platforms draw on data from the
Amanuel Psychiatric Hospital (the only psychiatric hospital in
Ethiopia at the time data were collected) and the International
Drug Price Indicator Guide (http://erc.msh.org). Costs for plan-
ning and administration, training of staff and monitoring
and evaluation at a national, provincial and district level are
included in the total cost. Total costs are counted over the 10-year
period that interventions are implemented and are discounted
at 3%.
Household financial burden
Depression, schizophrenia, epilepsy and bipolar disorder impose a
financial burden on households. First, we quantify what households
would pay due to illness-related cost in the absence of the pro-
gramme (as it is today). Since the current coverage of mental health
care is low in Ethiopia, the mental health programme is expected to
represent very little cost savings from a household perspective.
Before the MN programme is introduced, we assume that individ-
uals with access to MN care pay OOP for 34% of all provider costs
for treatment that currently is available (the national average OOP
expenditures on health services in Ethiopia) (World Bank and World
Development Indicators, Federal Democratic Republic of Ethiopia
Ministry of Health, 2014). The government finances the remaining
66% of MN health care costs. The treatment demand varies by
income group in accordance to the prevalence distribution. Age-
specific prevalence was updated according to recent GBD2013 esti-
mates (Global Burden of Disease Study, 2015). Second, we estimate
the private expenditures averted by the universal public finance of
MN treatments and reducing the existing OOP expenditures to 0%
for each income quintile.
Financial risk protection
The approach applied for estimating FRP is described in great detail
elsewhere (Verguet et al. 2013, 2015a). A standard utility-based
model is applied to quantify what may be seen as a ‘fair’ societal
risk premium, where universal public financing of MN care is con-
sidered as a social insurance programme. We calculate the insurance
value of universal public finance of the Ethiopian MN policy by
using a money-metric-value of insurance as the outcome unit of FRP
(Verguet et al. 2015a; McClellan and Skinner 2006). This US$value
represents how much the society is willing to pay for eliminating
the financial risk individuals currently face due to MN disease.
Universal public finance delivers FRP benefits to patients by averting
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the existing OOP expenditures associated MN disorders. First, we
estimate the expected individual income before universal public fi-
nance of MN services by a function based on (McClellan and
Skinner 2006; Verguet et al. 2015a,b):





where p is the probability of getting a MN disease, Cov is the cur-
rent treatment coverage, c is the OOP expenditures to MN treat-
ment, y is income in quintile J. See Table 1 for details on the
parameters that are used as input. Second, we estimate the certainty
equivalent for the same individual, Yj*, by:





where U is a constant relative risk aversion utility function (Table 1).
The certainty equivalent estimates the amount of money the individual
is willing to have in order to obtain certainty in the expected OOP ex-
penditures averted from universal public finance. Third, total money-




ðEJðyÞ  YJ Þf yð Þdy: (3)
where f ðyÞ is the income distribution in the population proxied by a
Gamma density based on the GDP per capita and Gini index in
Ethiopia (Table 1) (Salem and Mount 1974). The insurance value is
simply the difference between the expected value of income before
universal public finance of MN services and the certainty equivalent.




Prevalence mental disorders across wealth strata
(poor; average; rich)
0.220; 0.135; 0.114 (Fekadu et al. 2014)
Treatment demand (prevalence) (Global Burden of Disease
Study 2015) Depression (age 15–29; 30–44; 45–60) 0.062; 0.068; 0.070
 Bipolar disorder (age 15–29; 30–44; 45–60) 0.009; 0.012; 0.024
 Schizophrenia (age 15–29; 30–44; 45–60) 0.002; 0.006; 0.006
 Epilepsy (age 15–29; 30–44; 45–60) 0.007; 0.006; 0.006
Population size (in millions, age 15–29; 30–44; 45–60) 29.1m; 15.8m; 8.1m (UN Population Division
2015)
Interventions
Efficacy: (Strand et al. 2015)
 Depression (SSRI, CBT, proactive case management) 31% disability/-38%remission/-35%incidence
 Bipolar disorder (valproate and psychosocial therapy) 65% disability/-65% case fatality
 Schizophrenia (haloperidol plus psychosocial treatment) 23% disability
 Epilepsy (phenobarbital) 43% disability/-60% remission
Target coverage of interventions: (Federal Democratic
Republic of Ethiopia
Ministry of Health 2012)
 Depression (by quintile, Q1-Q5) 0.3;0.3;0.3;0.3;0.3
 Bipolar disorder (by quintile, Q1-Q5) 0.5;0.5;0.5;0.5;0.5
 Schizophrenia and epilepsy (by quintile, Q1-Q5) 0.75;0.75;0.75;0.75;0.75
 Epilepsy (by quintile, Q1-Q5) 0.75;0.75;0.75;0.75;0.75
Costs
Hospitalization cost per patient admitted (2010 US$)
 Depression (utilization at this level) US$538 (0.03) (Strand et al. 2015)
 Bipolar disorder (utilization at this level) US$330 (0.08)
 Schizophrenia (utilization at this level) US$1,777 (0.47)
 Epilepsy (utilization at this level) US$275 (0.11)
Outpatient clinic cost per visit (2010 US$)
 Depression (utilization at this level) US$101 (0.25) (Strand et al. 2015)
 Bipolar disorder (utilization at this level) US$74 (0.31)
 Schizophrenia (utilization at this level) US$95 (0.50)
 Epilepsy (utilization at this level) US$85 (1.00)
Primary care (health center/health post), cost per visit (2010 US$)
 Depression (utilization at this level) US$133 (1.00) (Strand et al. 2015)
 Bipolar disorder (utilization at this level) US$64 (0.50)
 Schizophrenia (utilization at this level) US$123 (0.50)
 Epilepsy (utilization at this level) US$46 (1.00)
Gini index 0.3 (World Bank and World
Development Indicators,
2015)
GDP (2014 US$, million) US$54,798
GDP per capita (2014 US$) US$565
Total societal income per capita (US$, by quintile Q1–Q5) US$180; US$340; US$500; US$690; US$1110
Total societal income per capita aged 15-60
(US$, by quintile Q1–Q5)
US$330; US$630; US$910; US$1260; US$2040
Utility function as a function of individual income y y
1r
1r with r ¼ 3 (Verguet et al. 2015a,
McClellan and Skinner
2006)
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Productivity gains
Treatment of MN disorders is likely to provide other important wel-
fare gains, in particular productivity at the household and societal
levels. Therefore, and because we expected low FRP due to the low
current level of utilization of MN services, we explore the expected
productivity gains from scaling up the provision of depression care
and treatment to productive ages (age 15-60). We concentrate on de-
pression in this age group because the disease burden is high in
Ethiopia, and evidence indicates that depression has a substantial
impact on productivity (Clark et al. 2009, Goetzel et al. 2003).
Around 6% of the adult Ethiopian population is estimated to have a
depressive episode at any given time (Table 1), with an average dur-
ation of 8.4 months (Strand et al. 2015). Productivity is lost during
such episodes because of increased absence from work (absenteeism)
and decreased work performance when present at work (presentee-
ism) (Goetzel et al. 2003). Depression treatment programmes have
been shown to improve rates of employment by up to 5% in the
United Kingdom (Clark et al. 2009). In the United States, costs asso-
ciated with presenteeism have been estimated to be higher than the
costs of treatment (Goetzel et al. 2003).
To estimate the productivity impact across income groups from
scaling up treatment of depression in Ethiopia, we first adapt the
Goetzel et al. (2004) approach to presenteeism to the context of
Ethiopia. We use epidemiological, demographic, efficacy and cost
data from the contextualized CEA of mental health care in Ethiopia
(Strand et al. 2015) and updated data if available (see Table 1). The
average reduction in duration of a depressive episode due to treat-
ment was estimated to be 2.9 months (8.4 months * efficacy of
0.35). Second, this reduction in duration was converted to a reduc-
tion in absenteeism. Disability days (per month) due to depression
are estimated to be 2.9 in low-income settings (Alonso et al. 2011).
Hence, we assumed treatment would reduce the number of disability
days by 8.7 days in total (2.9*2.9) in Ethiopia. Subsequently, popu-
lation with depression, target coverage (30%) and an average daily
income (per wealth quintile in the productive age groups (age
15–60) were multiplied by this change in absenteeism (8.7 days) to
derive an estimate of the potential productivity gains in Ethiopia. In
addition, we made an adjustment that took into account that losses
in presenteeism were reduced by treatment. Patients with depression
were found to have 3.7 days with partial disability per month in
low-income countries (Bruffaerts et al. 2012). Partial disability
means that on-the-job productivity is reduced because of disease. It
was assumed that patients with depression had 1.2 full days lost per
month because of presenteeism, based on the assumption that each
partial day is equivalent to one-third of a full lost day. Subsequently,
the associated productivity gain was estimated using the same
method as for absenteeism.
All analyses were conducted using the R statistical package
(www.r-project-org) and PopMod developed by WHO-CHOICE.
Ethical clearance was obtained from the Institutional Review Board
at the Medical Faculty of Addis Ababa University.
Results
The expected annual cost of implementing the defined MN health
care package at specified target coverage levels is approximately
US$177 million (Table 2) for the whole country, equivalent to
around US$1.8 per capita. The return on this investment in total
population health gain exceeds 155 000 healthy life-years (Table 2),
the majority of which derives from treatment of depression and epi-
lepsy. The eliminated out-of-pocket spending by universal public
financing is low in Ethiopia (around US$1 million in total) due to
the low current utilization of MN health services (<5%). The return
in FRP is also extremely low, US$1,720 in total, for the same
Table 2. Dashboard of the annual expected outcomes from scaling up the mental and neurological health care package in Ethiopia
Outcome Income quintile Total
I II III IV V
Total cost of care (2014 US$, in 1 000, at target coverage)a,b
Schizophrenia 8 329 7 250 6 171 5 091 4 011 30 852
Bipolar disorder 11 988 10 435 8 881 7 327 5 772 44 404
Depression 17 467 15 247 13 013 10 766 8 506 65 000
Epilepsy 10 143 8 832 7 666 6 205 4 082 36 928
Healthy life-years gained (at target coverage)b
Schizophrenia 2 420 2 100 1 790 1 480 1 160 8 956
Bipolar disorder 5 480 4 770 4 060 3 350 2 640 20 306
Depression 16 390 14 350 12 290 10 210 8 090 61 332
Epilepsy 17 680 15 420 13 260 10 860 7 270 64 502
Private expenditures averted (2014 US$, in 1 000, at current coverage)c
Schizophrenia 22 19 16 13 11 81
Bipolar disorder 65 57 48 40 31 241
Depression 44 38 32 27 21 162
Epilepsy 149 130 113 91 60 544
Insurance value (2014 US$, at current coverage)d
Schizophrenia 0.9 0.3 0.2 0.2 0.1 1.6
Bipolar disorder 38 13 7 7 3 67
Depression 113 40 22 21 9 206
Epilepsy 835 271 154 141 42 1 443
aTotal costs¼ (direct government expenditures)þ (private expenditures, including out-of-pocket costs).
bTarget coverage associated with enhanced public financing for all income groups was set at 30% for depression treatment, 50% for bipolar disorder and 75%
for the other two disorders.
cPrivate expenditures averted¼ out-of-pocket spending that is eliminated by switching to public financing.
dInsurance value¼ financial risk protection provided, based on current coverage.
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reasons. However, the expected productivity gain of depression
treatment is substantially higher compared to the expected FRP.
Scaled-up depression treatment at 30% coverage is expected to re-
turn total productivity gains of around US$50.7 million per year in
Ethiopia (Table 3), which is close to 78% of the expected total cost
of the depression treatment programme.
The results shown in Table 2 and Figure 1 indicate that the
health benefits of the MN intervention packages are expected to be
progressive. The poorest quintile is expected to gain 41 970 healthy
life years in total for all MN treatments, whereas the richest quintile
has an expected gain of 19 160 healthy life years in total. The low-
income groups gain more healthy life years than the richest quintiles
due to the high disease burden in the lower income quintiles. Total
cost of care is also higher in the poorest groups due to the relatively
high treatment demand in these groups. The total annual cost of
MN health care is expected to be close to US$48 million in the poor-
est quintile and US$22 million in the richest quintile. Similarly, the
measured value of insurance is highest among the lowest income
group. Per invested US$1 in MN services in Ethiopia, the expected
FRP return is not more than US$0.00001.
The return on productivity from investing in MN health care in
Ethiopia seems to be substantially higher than the expected FRP.
From the results shown in Table 3, we see that scaled-up depression
treatment at 30% coverage could lead to total productivity gains
of around US$50.7 million per year. The largest benefits accrue
to the wealthier quintiles on account of their higher average in-
come level. Our estimates indicate that the expected productivity
gain from scaled-up treatment of depression is likely to reduce the
governmental cost of the depression treatment programme by close
to 78%.
Discussion
The ECEA methodology is a novel approach to the economic ana-
lysis of mental health policies. It offers quantitative insights on how
MN interventions impact several important equity outcomes. This
analysis finds that health gains and productivity gains seem to be the
most important benefits from scaled-up universal public finance of
treatment for epilepsy, depression, bipolar affective disorder and
schizophrenia in Ethiopia. Public finance of these MN services yields
little prevention of impoverishment due to the low current level of
private OOP health care spending. The main reason for this is sim-
ply that patients are not impoverished in this way to start with since
MN services in Ethiopia are not available for most patients.
However, the private household economy seems to indirectly benefit
substantially from increased household income. Patients with de-
pression are expected to increase their income when offered depres-
sion treatment as they will be less absent from work and more
productive when they are at work.
Our results show a large expected increase in healthy life years if
the goals of the National Mental Health Strategy in Ethiopia is
achieved. That is, to substantially expand coverage of essential treat-
ment for schizophrenia (75% target coverage), bipolar disorder (tar-
get coverage 50%), depression (30% target coverage) and epilepsy
(target coverage 75%). Good health, or health benefits, is an import-
ant social good in itself. The WHO Consultative Group on Equity
and Universal Health Coverage identified health benefits to be more
important than financial risk protection (World Health Organisation
2014). This international group of ethicists considered it ethically
unacceptable to give high priority to costly services that are expected
to provide large FRP and small health benefits compared to less
costly services that provide substantial health benefits and low FRP
(World Health Organisation 2014).
The ECEA methodology uses the current utilization of MN
services as reference to how much FRP one can expect from a uni-
versal public finance of MN treatment. Public finance of MN ser-
vices does therefore not seem to protect households in Ethiopia from
Table 3. Expected productivity impact and net societal cost (2014 US$) of scaled-up depression treatment to 30% coverage
Cost/outcome Income quintile Total population
I II III IV V
Government cost of depression treatment programme (US$, million) 17.5 15.2 13.0 10.8 8.5 65.0
Productivity gain from scaled-up depression treatment (US$, million)a
• due to absenteeism 3.8 6.3 7.5 8.3 10.0 35.9
• due to presenteeism 1.6 2.6 3.1 3.4 4.1 14.8
Net societal cost of depression treatment programme (US$, million)b 12.0 6.3 2.4 0.9 5.6 14.3
aTotal societal income per capita in productive ages (15-60) (2014) in Ethiopia is US$1,034: by quintile, US$330 for QI, US$630 for QII, US$910 for QIII,
US$1260 for QIV and US$2,040 for QV.
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Figure 1. Level and distribution of expected healthy life years gained and pro-
gramme costs (2014 US$) with the introduction of universal public finance of
treatment for depression, bipolar disorders, schizophrenia and epilepsy ac-
cording to the National Mental Health Strategy in Ethiopia (I is the poorest
quintile and V the riches quintile).
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financial risks. Similarly, low levels of FRP from public finance of
antiepileptic drugs in India have been found (Megiddo et al. 2016).
Pneumococcal vaccines have an estimated insurance value of
US$66 000 at an 80% coverage according to a recent study from
Ethiopia (Johansson et al. 2015), substantially higher than the ex-
pected total FRP of US$1,720 from the National Mental Health
Strategy in Ethiopia. Universal public finance for tuberculosis treat-
ment in India is expected to give an insurance value of US$9,000,
where 80% of it would benefit the two poorest quintiles (Verguet et
al. 2015a). An ECEA from South Africa estimated households to
save US$0.29 per capita in OOP expenditures with an investment of
US$0.01 in a salt reduction policy (Watkins et al. 2016). The high
FRP from salt reduction is mainly due to the high current private
OOP spending on cardiovascular disease care in South Africa that
will be averted from the salt policy. Similar findings are found in an
Ethiopian ECEA, where interventions that avert the most cases of
poverty are a universal public finance of interventions with a high
level of OOP expenditures (caesarean section, tuberculosis treatment
and antihypertensives) (Verguet et al. 2015b).
However, scale-up of MN care in Ethiopia is estimated to give a
high return in productivity gains. A recent global return on invest-
ment analysis estimated an economic return of US$2.3-3.0 in prod-
uctivity gain per US$1 invested in treatment of depression and
anxiety in 36 countries between 2016 and 2030 (Chisholm et al.
2016). This global estimate is higher than our expected overall re-
turn rate of around US$0.8 per US$1 invested in depression treat-
ment in Ethiopia. We apply modest assumptions on disability days
averted to not overestimate the economic return. There is limited
evidence from low-income settings on days out of role in low- and
middle-income countries. We use average estimates that are derived
from contexts that are very different from the Ethiopian and there
may be major differences in occupational profile, among other.
Depression treatment programmes in United Kingdom (Clark et al.
2009) and the United States (Goetzel et al. 2003) are estimated to
offer somewhat higher productivity gains than our estimates from
Ethiopia. More work is needed for developing new methods to esti-
mate the productivity impact of MN interventions in low-income
settings where the context is vastly different to high-income settings.
Methods need to be sensitive to heterogeneous populations where
the majority live in remote rural settings and the rich middle class
live modern urban lives. More empirical evidence on how MN dis-
orders de-facto influences productivity in these settings is needed.
ECEA seems to be a feasible approach and a useful addition to
policy decision-making, particularly since it builds on existing cost-
effectiveness modeling frameworks. In our study, we used the planned
coverage rates presented in the National Mental Health Strategy in
Ethiopia and scaled them up over a 10-year period. The ministry of
health in Ethiopia has an ambitious strategy for mental health care in
the country, and we do not evaluate the feasibility of their goals. It
will be especially hard to reach the high target coverages in rural parts
of Ethiopia, where the majority of the population live, and it will
probably take >10 years to reach full coverage of all services.
Nonetheless, our results indicate that the expected health and prod-
uctivity gains are important returns to strive for.
This ECEA is subject to the inherent uncertainty surrounding
population-level projections of intervention costs, impacts and con-
sequences, consideration of which is contained in the primary ana-
lyses underlying the base case. Therefore, our findings from the
application of ECEA to the original CEA of MN disorders need to
be interpreted with a due degree of caution. The uncertainty of the
results in the existing CEA was in particular noteworthy for inter-
ventions targeting schizophrenia and bipolar disorder due to lack of
evidence (Strand et al. 2015). A method for systematically handling
uncertainty in ECEAs is not developed yet. In general, presentation
and interpretation of a sensitivity analysis for stratified analysis of
multiple parameters and outcomes are complex.
Variations of outcomes in this analysis are driven by the variation
of disease prevalence (Fekadu et al. 2014) and income level for five in-
come groups (World Bank and World Development Indicators). A
socioeconomic gradient is likely to exist for other parameter inputs as
well, but such stratified evidence is limited and we therefore decided
to hold values of other input parameters fixed across income groups.
For MN health care one could expect that it is costlier to reach the
poor than the rich with care, the current and target coverage is higher
among rich than poor, and the total OOP spending on MN health
care and efficacy of interventions will vary across income groups. The
stratified results for healthy life years gained, FRP, total governmental
costs and private expenditures averted are sensitive to variations in all
these parameters: A higher cost to reach the poor with services would
increase the total governmental cost, a higher increase in expansion of
coverage for the rich would reduce expected health benefits for the
poor and increase expected health benefits for the rich, and a higher
total OOP expenditure would increase the FRP of the National
Mental Health Strategy in Ethiopia. To be able to quantify the impact
of these variations, better evidence on the distribution of such policy-
relevant parameters and more systematic methods for doing sensitivity
analysis in ECEA are needed. The main data requirements for con-
ducting more precise ECEAs are stratified epidemiological and eco-
nomic input parameters. Such information may be available in
national demographic and health surveys, or could be built into future
data collections.
Conclusion
Findings from this ECEA indicate that investing in universal public
finance of public mental health will create substantial health benefits
and high productivity gains, but it will most likely produce a low de-
gree of FRP. Accordingly, while the ECEA approach captures FRP
and equity in the economic evaluation of mental health policy, the
FRP benefits are less relevant when the current utilization and
spending on care is extremely low, as they are in Ethiopia.
Nevertheless, we expect that many families experience impoverish-
ing loss of income because of mental disorders.
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